相关实验视频

Updated: Jul 5, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

扩散型大B细胞淋巴瘤治疗的新护理标准

Chathuri Abeyakoon^1,2,3, Gareth P Gregory^1,2

¹Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.

British journal of haematology

|January 22, 2024

概括

新的指导方针提供了基于证据的策略来治疗扩散性大B细胞淋巴瘤,超越标准的Rituximab和CHOP (R-CHOP) 治疗方案. 这些建议结合了最近的临床试验数据,以改善患者的治疗结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床指南临床指南

背景情况:

新诊断的扩散性大B细胞淋巴瘤 (DLBCL) 的标准治疗方法已经是20年来使用Rituximab和Cyclophosphamide,Doxorubicin,Vincristine和Prednisone (R-CHOP).
最近的随机临床试验产生了新的证据,影响DLBCL的治疗策略.

研究的目的:

提出最新的,基于证据的治疗策略,用于管理新诊断的扩散性大B细胞淋巴瘤.
根据最新的临床试验结果为临床医生提供指导.

主要方法:

准则的制定涉及随机临床试验的系统审查.
证据被评估使用既定的方法来为建议提供信息.

主要成果:

该指南包含了新的数据,建议对R-CHOP疗法进行潜在的修改或补充.
最近临床试验的积极结果支持修订的治疗方法.

结论:

英国血液学会的指导方针为新诊断的DLBCL提供了更新的管理策略.
临床医生应考虑这些基于证据的建议,以优化患者护理,超出传统的R-CHOP疗法.

关键词:

DLBCL DLBCL 是一个字母.化学疗法化疗化疗免疫疗法免疫疗法淋巴瘤是一种淋巴瘤.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...